Emerging targets and treatments in amyotrophic lateral sclerosis

The Lancet Neurology

Volumn 10, Issue 5, 2011, Pages 481-490

  Zinman, Lorne ^a   Cudkowicz, Merit ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 031; AMYLOID BETA PROTEIN; ANTISENSE OLIGONUCLEOTIDE; ARIMOCLOMOL; ARUNDIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CEFTRIAXONE; CILIARY NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; GABAPENTIN; GSK 1223249; ISIS 333611; LAMOTRIGINE; MEMANTINE; MINOCYCLINE; OLESOXIME; PEPTIDE VACCINE; PLACEBO; PRAMIPEXOLE; PROTEIN INHIBITOR; RILUZOLE; SMALL INTERFERING RNA; SNN 0029; SOMATOMEDIN; TALAMPANEL; TAMOXIFEN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; BRAIN MITOCHONDRION; DRUG EFFICACY; DRUG SAFETY; EMBRYONIC STEM CELL; FAMILIAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NEURAL STEM CELL TRANSPLANTATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE THERAPY; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; RECEPTOR UPREGULATION; REVIEW; RNA INTERFERENCE; STEM CELL TRANSPLANTATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; RILUZOLE; TREATMENT OUTCOME;

EID: 79954608945     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70024-2     Document Type: Review

References (106)

1. Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009, 72:725-731.
2. Alonso A, Logroscino G, Jick SS, Hernan MA Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 2009, 16:745-751.
3. Clinical trial ceftriaxone in subjects with ALS (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00349622?term=ceftriaxone+and+als&rank=1.
4. Phase II/III randomized, placebo-controlled trial of arimoclomol in SOD1 positive familial amyotrophic lateral sclerosis (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00706147?term=nct00706147&rank=1.
5. Cudkowicz ME, Shefner JM, Simpson E, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008, 38:837-844.
6. Urushitani M, Ezzi SA, Julien JP Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2007, 104:2495-2500.
7. Takeuchi S, Fujiwara N, Ido A, et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2010, 69:1044-1056.
8. Gros-Louis F, Soucy G, Lariviere R, Julien JP Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010, 113:1188-1199.
9. Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (SOD-1) (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT01041222?term=NCT01041222&rank=1.
10. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005, 11:423-428.
11. Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006, 116:2290-2296.
12. Wang H, Ghosh A, Baigude H, et al. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem 2008, 283:15845-15852.
13. Safety and efficacy of TRO19622 as add-on therapy to riluzole versus placebo in treatment of patients suffering from amyotrophic lateral sclerosis (ALS) (MITOTARGET) (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00868166?term=NCT00868166&rank=1.
14. Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007, 322:709-720.
15. Bozik ME KNS-760704-CL201, part 1: a 12-week phase 2 study of the safety, tolerability, and clinical effects of KNS 760704 in ALS subjects. Amyotroph Lateral Scler 2009, 10(suppl 1):28-29.
16. A safety and tolerability study of intracerebroventricular administration of sNN0029 to patients with amyotrophic lateral sclerosis (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00800501?term=NCT00800501&rank=1.
17. Zheng C, Nennesmo I, Fadeel B, Henter JI Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2004, 56:564-567.
18. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005, 8:85-92.
19. Vercelli A, Mereuta OM, Garbossa D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2008, 31:395-405.
20. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008, 265:78-83.
21. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009, 11:26-34.
22. Deda H, Inci MC, Kurekci AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009, 11:18-25.
23. Motor-point stimulation for conditioning the diaphragm of patients with amyotrophic lateral sclerosis (ALS) (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00420719?term=NCT00420719&rank=1.
24. Onders RKB, So Y, Katz J, et al. Positive clinical results of diaphragm pacing in ALS/MND with chronic hypoventilation and upper motor neuron respiratory deficits with intact lower motor neuron phrenic motor function. Amyotroph Lateral Scler 2010, 11(suppl 1):137.
25. A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT01089010?term=NCT01089010&rank=1.
26. Shefner J. Rationale and design for Phase lla Study evaluating CK-2017357, a novel activator of fast skeletal muscle, in patients with ALS. 21st International Symposium on ALS/MND; Orlando, FL, USA; Dec 11-13, 2010.
27. Borgstein NG, Barger R, Yang Y, et al. A phase 1 multiple ascending dose study to assess the pharmacodynamic effects of ACE-031, an inhibitor of negative muscle regulators, in healthy volunteers. 15th International Congress of the World Muscle Society; Kunamoto, Japan; Oct 12-16. Poster P3.18.
28. First Time in Human Study of GSK1223249 in amyotrophic lateral sclerosis (accessed Feb 17, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00875446?term=NCT00875446&rank=1.
29. Bensimon G, Lacomblez L, Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994, 330:585-591. the ALS/Riluzole Study Group.
30. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996, 347:1425-1431.
31. Shefner J, Meininger V Results of a clincal trial of Telampanel in patients with ALS. Amyotroph Lateral Scler 2010, 11(suppl 1):44-45. for the Telampanel ALS Study Group.
32. de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:456-460.
33. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003, 61:456-464.
34. Ryberg H, Askmark H, Persson LI A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003, 108:1-8.
35. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001, 56:843-848.
36. Information sheet no. N: ONO-2506PO clinical trial update Motor Neurone Disease Association, (accessed Feb 17, 2011). http://www.mndassociation.org/document.rm?id=191.
37. Rothstein JD, Patel S, Regan MR, et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
38. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
39. Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
40. Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010, 13:1396-1403.
41. Kerman A, Liu HN, Croul S, et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol 2010, 119:335-344.
42. Liu HN, Sanelli T, Horne P, et al. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann Neurol 2009, 66:75-80.
43. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007, 61:427-434.
44. Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001, 20:1774-1784.
45. Mackenzie IR, Rademakers R, Neumann M TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010, 9:995-1007.
46. Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, Durham HD Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 1999, 72:693-699.
47. Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 2003, 307:689-695.
48. Lindquist S The heat-shock response. Annu Rev Biochem 1986, 55:1151-1191.
49. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004, 10:402-405.
50. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
51. Kwiatkowski TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
52. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
53. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009, 106:18809-18814.
54. Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2010, 107:3858-3863.
55. Hirano A, Donnenfeld H, Sasaki S, Nakano I Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1984, 43:461-470.
56. Sasaki S, Iwata M Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996, 47:535-540.
57. Afifi AK, Aleu FP, Goodgold J, MacKay B Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology 1966, 16:475-481.
58. Atsumi T, Miyatake T Morphometry of the degenerative process in the hypoglossal nerves in amyotrophic lateral sclerosis. Acta Neuropathol 1987, 73:25-31.
59. Dupuis L, di Scala F, Rene F, et al. Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J 2003, 17:2091-2093.
60. Echaniz-Laguna A, Zoll J, Ribera F, et al. Mitochondrial respiratory chain function in skeletal muscle of ALS patients. Ann Neurol 2002, 52:623-627.
61. Vielhaber S, Winkler K, Kirches E, et al. Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 1999, 169:133-139.
62. Israelson A, Arbel N, Da Cruz S, et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 2010, 67:575-587.
63. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002, 13:1067-1070.
64. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.
65. Kriz J, Nguyen MD, Julien JP Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002, 10:268-278.
66. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004, 63:1656-1661.
67. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999, 5:347-350.
68. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
69. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003, 53:437-445.
70. Atassi N, Ratai EM, Greenblatt DJ, et al. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:508-513.
71. Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler 2008, 9:50-58.
72. Gribkoff VK, Bozik ME KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 2008, 14:215-226.
73. Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006, 316:189-199.
74. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999, 52:1427-1433. The BDNF Study Group (Phase III).
75. Bongioanni P, Reali C, Sogos V Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004, 3. CD004302.
76. Mitchell JD, Wokke JH, Borasio GD Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2002, 3. CD002064.
77. Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
78. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998, 51:583-586.
79. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997, 49:1621-1630.
80. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996, 46:1244-1249. ALS CNTF Treatment Study Group.
81. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001, 28:131-138.
82. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003, 34:383-394.
83. Lambrechts D, Poesen K, Fernandez-Santiago R, et al. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet 2009, 46:840-846.
84. Hynynen K Focused ultrasound for blood-brain disruption and delivery of therapeutic molecules into the brain. Expert Opin Drug Deliv 2007, 4:27-35.
85. Papadeas ST, Maragakis NJ Advances in stem cell research for Amyotrophic Lateral Sclerosis. Curr Opin Biotechnol 2009, 20:545-551.
86. Deshpande DM, Kim YS, Martinez T, et al. Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol 2006, 60:32-44.
87. Hall ED, Oostveen JA, Gurney ME Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
88. Barbeito LH, Pehar M, Cassina P, et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004, 47:263-274.
89. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
90. Beers DR, Henkel JS, Xiao Q, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006, 103:16021-16026.
91. Xu L, Ryugo DK, Pongstaporn T, Johe K, Koliatsos VE Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009, 514:297-309.
92. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67:1187-1194.
93. Badayan I, Cudkowicz ME Is it too soon for mesenchymal stem cell trials in people with ALS?. Amyotroph Lateral Scler 2008, 9:321-322.
94. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006, 5:140-147.
95. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005, 102:18117-18122.
96. Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010, 109:635-642.
97. Liu BP, Cafferty WB, Budel SO, Strittmatter SM Extracellular regulators of axonal growth in the adult central nervous system. Philos Trans R Soc Lond B Biol Sci 2006, 361:1593-1610.
98. Jokic N, de Aguilar JL Gonzalez, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005, 57:553-556.
99. Jokic N, de Aguilar JL Gonzalez, Dimou L, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006, 7:1162-1167.
100. Benatar M Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007, 26:1-13.
101. Kaufmann P, Levy G, Montes J, et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Latereral Scler 2007, 8:42-46. QALS Study Group.
102. Kaufmann P, Levy G, Thompson JL, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005, 64:38-43.
103. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:481-488.
104. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009, 66:227-234.
105. Schoenfeld DA, Cudkowicz M Design of phase II ALS clinical trials. Amyotroph Lateral Scler 2008, 9:16-23.
106. Cudkowicz M, Greenblatt D, Shefner J, et al. Ceftriaxone in ALS: results of stages 1 and 2 of an adaptive design safety, pharmacokinetic and efficacy trial. 20th International Symposium on ALS/MND; Berlin, Germany; Dec 8-10, 2009. Session 6B, C39.